Antibiotic resistance among *Helicobacter pylori* clinical isolates in Lima, Peru

Kevin F Boehnke1
Manuel Valdivieso2
Alejandro Bussalleu3
Rachael Sexton4
Kathryn C Thompson1
Soledad Osorio5
Italo Novoa Reyes3
John J Crowley4
Laurence H Baker2
Chuanwu Xi1

1Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI, USA; 2Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; 3Departamento Académico de Clínicas Médicas, Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Perú; 4Cancer Research and Biostatistics, Seattle, WA, USA; 5Dirección General de Salud Ambiental, Ministerio de Salud del Perú, Lima, Perú

**Objectives:** Gastric carcinoma is the most common cancer and cause of cancer mortality in Peru. *Helicobacter pylori*, a bacterium that colonizes the human stomach, is a Group 1 carcinogen due to its causal relationship to gastric carcinoma. While eradication of *H. pylori* can help prevent gastric cancer, characterizing regional antibiotic resistance patterns is necessary to determine targeted treatment for each region. Thus, we examined primary antibiotic resistance in clinical isolates of *H. pylori* in Lima, Peru.

**Materials and methods:** *H. pylori* strains were isolated from gastric biopsies of patients with histologically proven *H. pylori* infection. Primary antibiotic resistance among isolates was examined using E-test strips. Isolates were examined for the presence of the *cagA* pathogenicity island and the *vacA* m1/m2 alleles via polymerase chain reaction.

**Results:** Seventy-six isolates were recovered from gastric biopsies. Clinical isolates showed evidence of antibiotic resistance to 1 (27.6%, n=21/76), 2 (28.9%, n=22/76), or ≥3 antibiotics (40.8%). Of 76 isolates, eight (10.5%) were resistant to amoxicillin and clarithromycin, which are part of the standard triple therapy for *H. pylori* infection. No trends were seen between the presence of *cagA*, *vacA* m1, or *vacA* m2 and antibiotic resistance.

**Conclusion:** The rate of antibiotic resistance among *H. pylori* isolates in Lima, Peru, is higher than expected and presents cause for concern. To develop more targeted eradication therapies for *H. pylori* in Peru, more research is needed to better characterize antibiotic resistance among a larger number of clinical isolates prospectively.

**Keywords:** *H. pylori*, antibiotic resistance, Peru, amoxicillin

**Introduction**

*Helicobacter pylori* is a stomach bacterium that colonizes ~50% of people globally.1 *H. pylori* is the primary risk factor for gastric cancer — the third highest cause of global cancer morbidity.2 *H. pylori* infection rates are highly dependent on socioeconomic status; ~80% of those living in low socioeconomic areas of Latin America, Asia, and Eastern Europe are infected, compared with <20% of asymptomatic Caucasians in the USA.3 *H. pylori* infection is treatable with different regimens of antibiotics,4 and eradication of *H. pylori* is a recognized way to lower incidence of gastric cancer.5 However, recurrence of infection is variable,6,7 and the emergence of antibiotic resistance compromises treatment efficacy. Thus, determining the best course of treatment is important to improve treatment efficacy and to reduce recurrence of *H. pylori* infection.

Unfortunately, there is no broad consensus about an optimal antibiotic therapy for the treatment of *H. pylori*. For example, meta-analyses of European and Asian clinical data compared the standard triple therapy (amoxicillin, clarithromycin, and a proton-pump
inhibitor for 7–14 days) with 5- or 10-day quadruple therapy regimens (adding metronidazole or tinidazole to the triple therapy) and found that quadruple therapies are both significantly more effective and cheaper than the triple therapy.\textsuperscript{8–10} However, we previously published a study comparing eradication therapies in seven sites of six Latin American countries that showed that the 14-day triple therapy was superior to the 5-day concomitant quadruple therapy, and no different than the 10-day sequential quadruple therapy.\textsuperscript{11,12} These inconsistencies reflect localized differences in antibiotic use practices, such as the use of clarithromycin for upper respiratory infections.\textsuperscript{13}

The differences in efficacy of antibiotic therapy are supported by primary antibiotic resistance data. For example, \textit{H. pylori} resistance to amoxicillin varied widely between Africa (65.6%), Europe (0.5%), Asia (11.6%), and the Americas (2.2%).\textsuperscript{12} Even in the same region, patterns of resistance differ: within Central and Latin America, reported average metronidazole resistance varies from 30% in Argentina to 83% in Columbia, and tetracycline resistance varies from 2% in Brazil to 33% in Columbia.\textsuperscript{14} As such, characterizing local resistance patterns is important for selecting therapies with the highest likelihood of success.

Our research focused on Peru, where gastric cancer is the leading cancer killer in men and women combined.\textsuperscript{15} Thus, we searched the literature for reports of primary antibiotic resistance to \textit{H. pylori} in Peru. Three studies were identified, which reported 36.9% resistance to levofloxacin,\textsuperscript{16} an average of 66% resistance to metronidazole,\textsuperscript{17,18} 50% resistance to clarithromycin,\textsuperscript{17} and 0% resistance to tetracycline.\textsuperscript{17} Unfortunately, there were no data on amoxicillin, and the reported results of other antibiotics were based on small sample sizes, so whether their results are generalizable is unknown.

As successful eradication of \textit{H. pylori} infection is an important step toward prevention of gastric carcinoma,\textsuperscript{5,19} we assessed primary \textit{H. pylori} antibiotic resistance among 76 isolates from a cohort of patients recruited in Lima, Peru, measuring resistance to metronidazole, amoxicillin, tetracycline, clarithromycin, levofloxacin, and rifampicin to cover the gamut of antibiotics used from initial through second- and third-line therapies.\textsuperscript{11,20} Our data showed significant primary antibiotic resistance to first- and second-line antibiotics among \textit{H. pylori} isolates from a clinical setting in Lima, Peru.

\section*{Materials and methods}

\subsection*{Patient recruitment, treatment, and sample collection}

The study protocol was approved by the Ethics Committee of the Universidad Peruana Cayetano Heredia in Lima, Peru, and the Institutional Review Board of the University of Michigan in Ann Arbor, MI, USA. The cohort of patients from whom \textit{H. pylori} isolates were obtained has been previously described.\textsuperscript{21} All experiments were conducted under the registered Clinical Trial Gob NCT015128, and SWOG clinical trial S1119. Briefly, patient recruitment occurred between September 2011 and August 2013 at the clinical facilities of the Universidad Peruana Cayetano Heredia Hospital in Metropolitan Lima. Signed, informed patient consent for procedures, antibiotic treatment, follow-up, and downstream molecular analyses were obtained before enrollment in the trial. Study participants were aged 20–70 years and had symptoms of dyspepsia for at least 6 months. Patients with gastric cancer or peptic ulcer disease were excluded from this study. Stomach biopsies were obtained via endoscopy under sedation from 109 adult symptomatic patients. The diagnosis of \textit{H. pylori} infection was made histologically. Six biopsies per patient were obtained: four for histologic studies and two for culture, which were stored in 1.5 mL of 1× phosphate-buffered saline (PBS) with 20% glycerol at −80°C until processing. Following endoscopy, infected patients were treated with esomeprazole, amoxicillin, and clarithromycin twice a day for 14 days. Indigent patients received treatment free of charge. Patients were followed up 1 year after treatment to check for \textit{H. pylori} infection status via the urea breath test.\textsuperscript{21}

\section*{\textit{H. pylori} isolation}

Gastric biopsy samples were thawed on ice and then homogenized using OMNI probes at maximum speed (Omni International, Kennesaw, GA, USA). A volume of 50 μL of the homogenized sample was plated onto both 5% Sheep’s Blood Tryptic Soy Agar plates (Remel, Columbus, OH, USA) and on \textit{H. pylori} selective media (Columbia blood agar base with 10% horse blood, 10 mg/L vancomycin, 5 mg/L trimethoprim, 5 mg/L cefsulodin, 5 mg/L amphotericin B, 300 mg/L urea, and 3500 U polymyxin B/L).\textsuperscript{22} Plates were incubated at 37°C in microaerobic conditions for 3–7 days. Presumptive \textit{H. pylori} isolates were subcultured, then confirmed by morphology and checked for urease activity using a urease indicator broth (0.33 M urea, 0.2% phenol red, 0.02% NaN\textsubscript{3}, 0.01 M NaPO\textsubscript{4} buffer [pH 6.5]). Glycerol stocks of each isolate were prepared in Bruccella Broth (Remel) with 15% glycerol.

\subsection*{Detecting vacA and cagA with PCR}

\textit{H. pylori} isolated DNA was tested for the presence of \textit{H. pylori} cagA and vacA genes by polymerase chain reaction (PCR) using previously described primers and the Takara

\section*{Infection and Drug Resistance 2017:10}
PCR kit (Clontech, Mountain View, CA, USA). For cagA, primers F1 (5′-GATAACGAGCTTGGTGGG-3′) and B1 (5′-CTGAAAGATTGTTTGGAGG-3′) were used to amplify a 349 base pair product. Primers VAG-F (5′-CAATCTGTCCAATCAAGCGAG) and VAG-R (5′-GCCTCGAAAAAATATTCCAGG) were used to amplify the m1/m2 subunits of the vacA gene, yielding a 570 or 645 base pair product. PCR products were visualized on a 1.5% agarose gel.

Antibiotic resistance and breakpoints
Using a protocol adapted from the University of Michigan Health System Clinical Microbiology laboratory and bioMérieux’s (Durham, NC, USA) instructions, H. pylori isolates were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole, rifampicin, and tetracycline using E-test. Isolates were subcultured and then grown on Mueller Hinton agar supplemented with 5% sheep’s blood (Remel, Columbus, Ohio, USA). Colonies were collected and suspended in 1× PBS and visually compared with a 3.0 McFarland turbidity standard. Cell suspensions were then spread on Mueller Hinton agar with 5% sheep’s blood (MH) and stored for 15 minutes in microaerobic conditions, allowing the suspension to dry on the plate. Then, E-test strips were placed on the plates with sterile forceps, and the plates were incubated for 72 hours at 37° C in microaerobic conditions. Results were interpreted per the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards, which are “based on epidemiological cut-off values, which distinguish wild-type isolates from those with reduced susceptibility”. Antibiotic resistance MICs were examined using descriptive statistics. Student’s t-tests were used to examine whether isolates with the m1 versus m2 subunit of the vacA gene were resistant to different numbers of antibiotics.

Statistical analysis
Antibiotic resistance MICs were examined using descriptive statistics. Student’s t-tests were used to examine whether isolates with the m1 versus m2 subunit of the vacA gene were resistant to different numbers of antibiotics.

Results
Seventy-six H. pylori strains were isolated from the gastric biopsies and were tested for primary antibiotic resistance (Table 2). Metronidazole was the antibiotic to which isolates were most commonly resistant (61.8%), while isolates showed least resistance to tetracycline (3.9%). About one-third of isolates were resistant to either clarithromycin or amoxicillin, which are typically used for the standard triple therapy, and 10.5% were resistant to both (Table 3). Further, 40.1% of strains were resistant to >3 of the tested antibiotics.

Polymerase chain reaction
By PCR, all 76 strains were positive for the cagA pathogenicity island, 57 (75%) were positive for vacA m1 and 19 (25%) were positive for vacA m2. No differences were seen between the presence of vacA m1/m2 and the mean number of antibiotics to which isolates were resistant.
Discussion

To our knowledge, this is the first study characterizing *H. pylori* primary antibiotic resistance to amoxicillin and rifampicin in Peru. When comparing our study results to published studies, we found that the MIC cutoffs were inconsistent between studies. Using a mini-well agar dilution method to determine antibiotic resistance, Vasquez et al used a clarithromycin MIC of 0.125 and a metronidazole MIC of 4 mg/L,16 rather than the EUCAST cutoffs of 0.5 and 8, respectively. Our study showed comparable primary antibiotic resistance among *H. pylori* isolates to metronidazole, and slightly higher resistance to clarithromycin and levofloxacin.15,26 We conducted a brief meta-analysis compiling all primary antibiotic resistance data in Peru from ours and other reports from the literature (Table 4).

This study demonstrates a high incidence of primary *H. pylori* antibiotic resistance in Lima, Peru, to antibiotics used in the standard triple therapy. Inference from our results is limited due to our small sample size and that our patient population is likely not generalizable to Peru. However, we noted some important trends in our data and resulting meta-analysis. First, the small percentage of isolates resistant to tetracycline is worth examining in future studies to see if this trend holds. Second, virtually all clinical isolates tested were resistant to one or more of the antibiotics commonly used to treat this infection, including amoxicillin, clarithromycin, levofloxacin, and metronidazole. This may contribute to the lower than anticipated response to *H. pylori* therapy observed in other parts of Latin America.11,26 This overall pattern of antibiotic resistance suggests that it may be worth considering treatment alternatives for *H. pylori* infection in Lima, Peru. We suggest that clinicians consider testing the antibiotic resistance profile of clinical isolates from patients with treatment-resistant infection as a way to guide their treatment decisions.

An emerging appearance of *H. pylori* antibiotic resistance has also been reported from other parts of the world, including Asia, Europe, and the Americas.12,15–17,19,26–28 This observation, coupled with reports of *H. pylori* reinfection after successful antibiotic treatment,6,29 makes *H. pylori* treatment more challenging. Meanwhile, gastric cancer remains one of the most common and most lethal cancers in men and women combined in Peru.2,14 After accounting for emerging patterns of antibiotic resistance of *H. pylori*, it might be useful to reconsider present treatment practices while investigating new therapies and considering testing of *H. pylori* clinical isolates for antibiotic sensitivity in certain regions of the world, such as Peru.

Table 2 Primary antibiotic resistance of clinical isolates from Lima, Peru

| Resistance cutoff (mg/L) | Amoxicillin | Clarithromycin | Tetracycline | Levofloxacin | Metronidazole | Rifampicin |
|--------------------------|-------------|----------------|--------------|--------------|---------------|------------|
| Isolates susceptible (%) | >0.125      | 0.5            | >1           | >1           | >8            | >1         |
| Isolates resistant (%)   | 51/76 (67.1)| 49/76 (64.5)   | 73/76 (96.1) | 35/76 (46.1) | 29/76 (38.2)  | 41/76 (53.9) |
| MIC50 (mg/L)             | 0.655       | 0.94           | 3            | 0.048        | 256           | 0.875      |
| MIC90 (mg/L)             | 256         | 256            | 32           | 0.125        | 256           | 32         |
| MIC range (mg/L)         | 0–256       | 0–256          | 0.25–32      | 0.032–32     | 0.25–256      | 0–256      |

Notes: Results of MIC testing using E-test strips from bioMérieux. Susceptibility and resistance were determined using EUCAST standards. *Five isolates had a 0.5-µg/mL MIC for clarithromycin, which falls between the susceptible and resistant cutoffs for clarithromycin. For the purposes of this analysis, they were considered resistant.

Abbreviation: MIC, minimum inhibitory concentration.

Table 3 Primary resistance to >1 antibiotic among clinical isolates

| No. resistance | 1 | 2 | 3+ | Resistant to clarithromycin and amoxicillin |
|----------------|---|---|----|------------------------------------------|
| Number of isolates, n/N (%) | 2/76 (2.6) | 21/76 (27.6) | 22/76 (28.9) | 31/76 (40.8) | 8/76 (10.5) |

Notes: Nearly all isolates were resistant to at least one antibiotic, and 70% were resistant to two or more. Eight of 76 isolates were resistant to both clarithromycin and amoxicillin, which are both used in the triple therapy.

Table 4 Reported primary antibiotic resistance among *Helicobacter pylori* isolates from Peru using EUCAST guidelines

| Study            | Amoxicillin, % | Clarithromycin, % | Tetracycline, % | Levofloxacin, % | Metronidazole, % | Rifampicin, % |
|------------------|----------------|-------------------|-----------------|-----------------|------------------|---------------|
| Vasquez et al14  | N/A            | 38.9 (7/18)       | 0 (0/5)         | N/A             | 27.8 (5/18)      | N/A           |
| Berg et al17     | N/A            | 4.2 (1/24)        | N/A             | N/A             | 63.6 (49/77)     | N/A           |
| Mochizuki Tamayo et al15 | N/A | N/A | N/A | 36.8 (35/95) | N/A | N/A |
| Totals, including present study | 32.9 (25/76) | 29.7 (34/118) | 3.7 (3/81) | 44.4 (76/171) | 59.1 (101/171) | 46.1 (35/76) |

Notes: Meta-analysis of primary antibiotic resistance among isolates from all studies in Peru. *Six isolates had a clarithromycin MIC of 0.5 mg/L. For the purposes of this meta-analysis, we counted them as resistant.

Abbreviations: MIC, minimum inhibitory concentration; N/A, not applicable.
Conclusion

We show high rates of primary antibiotic resistance to *H. pylori* clinical isolates in Lima, Peru. More studies are needed to confirm this finding to optimize the clinical treatment of *H. pylori* infection in Peru.

Acknowledgments

The authors wish to thank Dr. Jorge Huerta Mercado, Jefe del Servicio de Gastroenterología del Hospital Cayetano Heredia, Lima, Peru, and all members of his GI team; Licenciada en Enfermería Claudia Meza, del Servicio de Gastroenterología del Hospital Cayetano Heredia, Lima, Peru; Alfredo A. Rodriguez, Consultant, Civil and Sanitation Engineer; Biólogo Jorge Mucha and Engineer Leopoldo Goetendia, both from the Dirección de Saneamiento Basico, Dirección General de Salud Ambiental, Ministry of Health, Lima, Peru; Laboratorios Farmindustria, Lima, Peru, for their generous donation of anti-*H. pylori* triple antibiotic therapy for indigent participants on this study; and Dr. Gary Goodman, MD, for his input on this study.

This work was supported, in part, by The Hope Foundation, Ann Arbor, MI, USA; The Graham Sustainability Institute, University of Michigan; The Center for Global Health, University of Michigan; and the National Cancer Institute, Division of Cancer Prevention, NCI Community Oncology Research Program (NCORP) Research Base grant to SWOG (1U1G1CA189974–01). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author contributions

All authors participated in the design and conduct of the study. MV, AB, and INR directed the clinical trial. CX, KFB, KCT, and SO conducted the laboratory studies. RS performed the statistical analyses. All authors reviewed, critically revised, and approved the final manuscript.

Disclosure

LHB receives personal fees from Teva Pharmaceutical Industries Ltd. and Morphotek, Inc., for consulting/advisory role and is outside of the submitted work. All other authors report no conflicts of interest in this work.

References

1. Khalifa MM, Sharaf RR, Aziz RK. *Helicobacter pylori*: a poor man’s gut pathogen? *Gut Pathog*. 2010;2(1):2.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E380.
3. Sari Y-S, Can D, Tunali V, Sahin O, Koc O, Bender O. *H pylori*: Treatment for the patient only or the whole family? *World J Gastroenterol*. 2008;14(8):1244–1247.
4. Graham DV, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut*. 2010;59(8):1143–1153.
5. Lee YC, Chiang TH, Chou CK, et al. Association between *Helicobacter pylori* eradication and gastric cancer incidence: a systematic review and meta-analysis. *Gastroenterology*. 2016;150(5):1113–1124.e5.
6. Soto G, Bautista CT, Roth DE, et al. *Helicobacter pylori* reinfection is common in Peruvian adults after antibiotic eradication therapy. *J Infect Dis*. 2003;188(9):1263–1275.
7. Ramirez-Ramos A, Gilman RH, Leon-Baru A, et al. Rapid recurrence of *Helicobacter pylori* infection in Peruvian patients after successful eradication. *Clin Infect Dis*. 1997;25(5):1027–1031.
8. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for *Helicobacter pylori* infection in patients naive to treatment. *Ann Intern Med*. 2008;148(12):923–931.
9. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for *Helicobacter pylori* infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol*. 2009;104(12):3069–3079; quiz 1080.
10. Essa AS, Kramer JR, Graham DV, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for *Helicobacter pylori* eradication. *Helicobacter*. 2009;14(2):109–118.
11. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: a randomized trial. *Lancet*. 2011;378(9790):507–514.
12. Morgan DR, Torres T, Sexton R, et al. Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA*. 2013;309(6):578–586.
13. de Francesco V, Giorgio F, Hassan C, et al. Worldwide *H. pylori* antibiotic resistance: a systematic review. *J Gastrointest Liver Dis*. 2010;19(4):409–414.
14. Camargo MC, Garcia A, Riquelme A, et al. The problem of *Helicobacter pylori* resistance to antibiotics: a systematic review in Latin America. *Am J Gastroenterol*. 2014;109(4):485–495.
15. Pilco P, Payet E, Cáceres E. [Gastric cancer in Lima]. *Rev Gastroenterol Peru*. 2006;26(4):377–385. Available from: http://europepmc.org/abstract/med/17211488. Accessed September 25, 2015. Spanish.
16. Mochizuki Tamayo H, Noriega Aladve AP. [Antimicrobial susceptibility of *Helicobacter pylori* to levofloxacin determined in a miniwell format and disk diffusion tests using egg yolk agar]. *Rev Gastroenterol Peru*. 2011;31(3):224–229. Spanish.
17. Vasquez A, Valdez Y, Gilman RH, et al. Metronidazole and clarithromycin resistance in *Helicobacter pylori* determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. *Am Soc Microbiol*. 1996;34(5):1232–1234.
18. Berg DE, Gilman RH, Lehwala-Guruge J, et al. *Helicobacter pylori* populations in Peruvian patients. *Clin Infect Dis*. 1997;25(5):986–1002.
19. Wong BC-Y, Lam SK, Wong WM, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA*. 2004;291(2):187–194.
20. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for *Helicobacter pylori* infection. *World J Gastroenterol*. 2006;12(15):2313–2319.
21. Valdivieso M, Bussalleu A, Sexton R, et al. Clinical, epidemiologic, and genomic studies (SWOG S1119) of *Helicobacter pylori* infection in seven Latin American sites: a randomized trial. *Lancet*. 2010;376(9763):507–514.
22. Boehnke KF, Eaton KA, Valdivieso M, Baker LH, Xi C. Animal model reveals potential waterborne transmission of *Helicobacter pylori* infection. *Helicobacter*. 2015;20(5):326–333.
23. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut. 1997;41(4):442–451.

24. Atherton JC, Cover TL, Twells RJ, Morales MR, Hawkey CJ, Blaser MJ. Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of Helicobacter pylori. J Clin Microbiol. 1999;37(9):2979–2982.

25. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. Available from: http://www.eucast.org. Accessed October 4, 2016.

26. Camargo MC, García A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. 2014;109(4):485–495.

27. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18(4):274–279.

28. Caliskan R, Tokman HB, Erzin Y, Sarıhas S, Yüksel P. Major Article strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278–284.